Understand the access landscape
What can anchor drugs tell us about the path to access?
Run bespoke analysis to answer your specific launch questions — from coding requirements and detailed UM criteria to care-program requirements, at the plan level, historically or in real time — helping account teams prioritize plans and shape launch strategy.What changed in coverage last week?
Every policy re-read on its own cycle, with the diff shown against the paragraph it replaced — not a notification that something, somewhere, moved. Effective and revision dates are kept apart, because a payer approves on one date and applies on another.One change, tracked to the line
Step therapy: two preferred agents required
Revised
2026-06-18
Effective
2026-07-01
Veltraxa 2 required · Ondaresse 0 · Timrelvo 0
CMH-CP-0412 · p.4 · §III.B.2 · ll.141–144
What is our class required to do that we are not — and the reverse?
The same parity comparison across every drug in the class, on every plan, from the documents themselves — the drugs, never the vendors. Where the class is restricted and you are not is a position worth defending.Veltraxa against Ondaresse and Timrelvo
- Step therapy requirement
- Veltraxa 2 required · Ondaresse 0 · Timrelvo 0
- Quantity limit
- Veltraxa 2/56d · Ondaresse 2/28d · Timrelvo 2/28d
- Prescriber restriction
- Veltraxa attestation required · Ondaresse none · Timrelvo none
Three restrictions, on three plans, out of 47 read.
Which plans will matter on day one?
Covered lives, existing class restrictions and the coding files a new product lands against — read before the launch plan is fixed, not after the first denial. A product with no coverage history still lands into a class that has one.Read on every cycle
formulariesprior authorization criteriasite-of-care restrictionsgovernment coding filesbenefit designsUM rules
4,182 documents · 47 plans, each on its own schedule